Inventor · disambiguated record
Yan Lan
Also filed as: LAN YAN
7 granted patents·15 pending applications·147 citations·filing 1999–2022
86Inventor score
Top patents by PatentIndex Score
22 records- 0196US6838260B2Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulationEMD LEXIGEN RES CT CORP·Filed 2001·Granted Jan 4, 2005·78 cites·8 claims
- 0294US7226998B2Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulationEMD LEXIGEN RES CT CORP·Filed 2004·Granted Jun 5, 2007·35 cites·8 claims
- 0393US7576193B2Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulationMERCK PATENT GMBH·Filed 2007·Granted Aug 18, 2009·11 cites·8 claims
- 0489US7879319B2Heterodimeric fusion proteins useful for targeted immune therapy and general immune stimulationMERCK PATENT GMBH·Filed 2009·Granted Feb 1, 2011·8 cites·3 claims
- 0579US7517526B2Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agentsMERCK PATENT GMBH·Filed 2001·Granted Apr 14, 2009·12 cites·17 claims
- 0670US8420087B2Interleukin-12 targeted to oncofoetal fibronectinGILLIES STEPHEN·Filed 2005·Granted Apr 16, 2013·3 cites·10 claims
- 0764US2022017621A1Combination Therapy for CancerMERCK PATENT GMBH·Filed 2021·Application pending·0 cites
- 0863US2009088561A1Enhancing the circulating half-life of antibody-based fusion proteinsMERCK PATENT GMBH·Filed 2008·Application pending·0 cites
- 0958US2010297060A1Enhancement of antibody-cytokine fusion protein mediated immune responses by combined treatment with immunocytokine uptake enhancing agentsMERCK PATENT GMBH·Filed 2009·Application pending·0 cites
- 1057US2024279338A1Combination Treatment of CancerARES TRADING SA·Filed 2022·Application pending·0 cites
- 1157US2006194952A1Enhancing the circulating half-life of antibody-based fusion proteinsEMD LEXIGEN RES CT CORP·Filed 2006·Application pending·0 cites
- 1255US2008025947A1Methods for enhancing the efficacy of IL-2 mediated immune responsesMERCK PATENT GMBH·Filed 2007·Application pending·0 cites
- 1353US2023372319A1Combination Treatment of CancerARES TRADING SA·Filed 2021·Application pending·0 cites
- 1452US2023159465A1ImmunomodulatorHITGEN INC·Filed 2022·Application pending·0 cites
- 1551US2013017168A1Methods for enhancing the efficacy of il-2 mediated immune responsesMERCK PATENT GMBH·Filed 2012·Application pending·0 cites
- 1651US2023227437A1ImmunomodulatorHITGEN INC·Filed 2022·Application pending·0 cites
- 1751US2018118832A1Combination therapy for cancerMERCK PATENT GMBH·Filed 2017·Application pending·0 cites
- 1848US2023044248A1COMBINED INHIBITION OF PD-1, TGFBeta AND ATM TOGETHER WITH RADIOTHERAPY FOR THE TREATMENT OF CANCERARES TRADING SA·Filed 2020·Application pending·0 cites
- 1947US2021113656A1Treatment of stage iii nsclc and mitigation of pathological conditions associated with the treatmentMERCK PATENT GMBH·Filed 2020·Application pending·0 cites
- 2043US2021246208A1Combined inhibition of pd-1/pd-l1, tgfb and dna-pk for the treatment of cancerMERCK PATENT GMBH·Filed 2019·Application pending·0 cites
- 2139US11149008B2Sulfamide derivatives and preparation method and use thereofHITGEN LTD·Filed 2016·Granted Oct 19, 2021·0 cites·26 claims
- 2232US2003105294A1Enhancing the circulating half life of antibody-based fusion proteinsFiled 1999·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Yan Lan files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →